Screener
Aclaris Therapeutics ACRS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $15,516 | $13,158 |
| Accrued expenses | 5,959 | 8,791 |
| Deferred income | 3,976 | 3,943 |
| Other current liabilities | 2,790 | 2,753 |
| Total current liabilities | 28,241 | 28,645 |
| Other liabilities | 1,262 | 1,565 |
| Deferred income, net of current portion | 14,309 | 16,168 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's deferred revenue?
- Aclaris Therapeutics (ACRS) reported deferred revenue of $3.98M in Q2 2026.
- How has Aclaris Therapeutics's deferred revenue changed year-over-year?
- Aclaris Therapeutics's deferred revenue increased by 1.6% year-over-year, from $3.91M to $3.98M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Aclaris Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude